Comparison of reduced nine-paired joint set with existing six-paired and seven-paired joint sets: change in GLOESS and components
| Joint count | n | Mean change baseline to week 24 (95% CI) | SRM | |
|---|---|---|---|---|
| Nine-paired* joint set | 84 | GLOESS | –6.4 (–7.9 to –4.9) | –0.95 |
| SH | –6.1 (–7.5 to –4.7) | –0.95 | ||
| PD | –5.2 (–6.5 to –3.9) | –0.86 | ||
| JE | –3.4 (–4.6 to –2.1) | –0.59 | ||
| Six-paired† joint set24 | 85 | GLOESS | –5.3 (–6.5 to –4.2) | –0.99 |
| SH | –5.1 (–6.2 to –4.0) | –0.99 | ||
| PD | –4.8 (–5.8 to –3.8) | –1.02 | ||
| JE | –2.9 (–3.8 to –1.9) | –0.65 | ||
| Seven-paired‡ joint set25 | 85 | GLOESS | –6.6 (–8.0 to –5.3) | –1.05 |
| SH | –6.3 (–7.6 to –5.0) | –1.07 | ||
| PD | –6.2 (–7.5 to –4.9) | –1.04 | ||
| JE | –3.2 (–4.3 to –2.1) | –0.63 |
n=number of patients with both baseline and postbaseline measurements.
*MCP1, MCP4, PIP2, wrist, shoulder, elbow, knee, MTP3, MTP5 bilaterally.
†MCP2, MCP3, wrist, elbow, knee, ankle bilaterally.
‡MCP2, MCP3, PIP2, PIP3, wrist, MTP2, MTP5 bilaterally. Excludes PDUS score from sites that experienced technical and quality issues with PDUS scoring and compliance issues.
GLOESS, Global OMERACT–EULAR (Outcome Measures in Rheumatology–European League Against Rheumatism) Synovitis Score; JE, joint effusion; MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; PD, power Doppler; PDUS, PD and greyscale ultrasound; PIP, proximal interphalangeal joint; SH, synovial hyperplasia; SRM, standardised response mean.